Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ofatumumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis Data Support Kesimpta In Relapsing MS After Oral Switch
    Novartis Data Support Kesimpta In Relapsing MS After Oral Switch

    24 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/24/3155199/0/en/New-Novartis-data-further-support-benefits-of-Kesimpta-in-relapsing-MS-following-switch-from-oral-disease-modifying-therapies.html

    GLOBENEWSWIRE
    24 Sep 2025
    Share Share
    Alvotech, Advanz Pharma Extend Partnership for 3 More Biosimilars
    Alvotech, Advanz Pharma Extend Partnership for 3 More Biosimilars

    28 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/28/3089259/0/en/Alvotech-and-Advanz-Pharma-Extend-Strategic-Partnership-to-Commercialize-Three-Additional-Biosimilars-in-Europe.html

    GLOBENEWSWIRE
    28 May 2025
    Share Share
    Novartis to present new data at AAN on Kesimpta® safety in MS.
    Novartis to present new data at AAN on Kesimpta® safety in MS.

    25 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/25/3048413/0/en/Novartis-to-present-new-data-at-AAN-including-seven-year-disability-outcomes-and-safety-analysis-of-Kesimpta-in-people-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    25 Mar 2025
    Share Share
    Novartis' Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.
    Novartis' Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.

    12 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    12 Apr 2024
    Share Share
    Novartis' Arzerra (ofatumumab) Receives Suppl Approval in the U.S.
    Novartis' Arzerra (ofatumumab) Receives Suppl Approval in the U.S.

    12 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    12 Apr 2024
    Share Share
    Novartis presents new five-year data disability outcomes and safety of Kesimpta
    Novartis presents new five-year data disability outcomes and safety of Kesimpta

    20 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/20/2650654/0/en/Novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-Kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    20 Apr 2023
    Share Share